Biogen
American multinational biotechnology company
BIIB Nasdaq
ISIN US09062X1037 SEC CIK 875045 LEI W8J5WZB5IY3K0NDQT671
Follow Biogen
Weekly email: filings, results
Revenue, last quarter
$2.8B
+10.6% vs same quarter last year
Net income
−$20.6M
−104.4% vs same quarter last year
EPS, diluted
−$0.14
−104.4% vs same quarter last year
Operating cash flow
$640.8M
−49.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $9.9B | $1.3B |
| FY24 | $9.7B | $1.6B |
| FY23 | $9.8B | $1.2B |
| FY22 | $10.2B | $3B |
| FY21 | $11B | $1.6B |
| FY20 | $13.4B | $4B |
| FY19 | $14.4B | $5.9B |
| FY18 | $13.5B | $4.4B |
| FY17 | $12.3B | $2.5B |
| FY16 | $11.4B | $3.7B |
| FY15 | $10.8B | $3.5B |
| FY14 | $9.7B | $2.9B |
| FY13 | $6.9B | $1.9B |
| FY12 | $5.5B | $1.4B |
| FY11 | $5B | $1.2B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 75.7% | - | 13.1% |
| FY24 | 76.1% | - | 16.9% |
| FY23 | 74.2% | - | 11.8% |
| FY22 | 77.6% | - | 30% |
| FY21 | 80.8% | 25.9% | 14.2% |
| FY20 | 86.6% | 33.8% | 29.8% |
| FY19 | 86.4% | 49% | 41% |
| FY18 | 86.5% | 43.8% | 32.9% |
| FY17 | 86.7% | 43.6% | 20.7% |
| FY16 | 87.1% | 45% | 32.3% |
| FY15 | 88.5% | 45.4% | 33% |
| FY14 | 87.9% | 40.9% | 30.2% |
| FY13 | 87.6% | 36.3% | 26.9% |
| FY12 | 90.1% | 33.6% | 25% |
| FY11 | 90.8% | 34.2% | 24.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $2.1B |
| FY24 | $2.7B |
| FY23 | $1.3B |
| FY22 | $1.1B |
| FY21 | $3.4B |
| FY20 | $3.8B |
| FY19 | $6.6B |
| FY18 | $5.4B |
| FY17 | $3.7B |
| FY16 | $4B |
| FY15 | $3.3B |
| FY14 | $2.7B |
| FY13 | $2.1B |
| FY12 | $1.6B |
| FY11 | $1.5B |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | $750M |
| FY21 | $1.8B |
| FY20 | $6.7B |
| FY19 | $5.9B |
| FY18 | $4.4B |
| FY17 | $1.4B |
| FY16 | $1B |
| FY15 | $5B |
| FY14 | $886.8M |
| FY13 | $400.3M |
| FY12 | $984.7M |
| FY11 | $498M |
- Biogen
- Healthcare median
Show the numbers
| Year | Biogen | Healthcare median |
|---|---|---|
| FY25 | 13.1% | −30.6% |
| FY24 | 16.9% | −47% |
| FY23 | 11.8% | −58% |
| FY22 | 30% | −80.4% |
| FY21 | 14.2% | −71.9% |
| FY20 | 29.8% | −62.2% |
| FY19 | 41% | −46.3% |
| FY18 | 32.9% | −49.6% |
| FY17 | 20.7% | −45.9% |
| FY16 | 32.3% | −36% |
| FY15 | 33% | −38.4% |
| FY14 | 30.2% | −35.5% |
| FY13 | 26.9% | −37.1% |
| FY12 | 25% | −29.1% |
| FY11 | 24.5% | −27.9% |